title: BioInvent Announces Initiation of BI-1206 Phase 2a Trial in Advanced or Metastatic NSCLC and Uveal Melanoma
source: Yahoo
date: 2025-10-08
url: https://finnhub.io/api/news?id=9cd8be60038dcf78df544954e9505309b9fc4d0c2165e4ec409d5846e1fa8f9b
LUND, SE / ACCESS Newswire / October 8, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...
